<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912457</url>
  </required_header>
  <id_info>
    <org_study_id>CEP0043/07</org_study_id>
    <nct_id>NCT00912457</nct_id>
  </id_info>
  <brief_title>Donepezil Treatment for Sleep Apnea Patients</brief_title>
  <acronym>doneapnea</acronym>
  <official_title>Donepezil Treatment for Sleep Apnea Patients: A Double Blind Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associacao Fundo de Incentivo a Psicofarmcologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Associacao Fundo de Incentivo a Psicofarmcologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the anticholinesterase drug
      donepezil on sleep apnea patients. Sleep structure and respiratory parameters will be
      analyzed by polysomnography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cholinergic activity also influences the upper airway opening via central and peripheral
      mechanisms. Decreased thalamic pontine cholinergic projections may affect respiratory drive
      leading to both central and obstructive apnea at least in certain degenerative conditions.In
      contrast to the prolific literature on physical and surgical treatments for sleep apnea there
      is a dearth of effective pharmacological approaches.Most drugs previously tested for this
      purpose acted upon monoaminergic and adenosinergic systems and showed unsuccessful or
      ambiguous results.A previous study showed that donepezil treatment improved apnea-hypopnea
      index and oxygen saturation in patients with Alzheimer's disease. Treatment also increased
      REM sleep duration and reduced ADAS-cog scores.Based on these facts we hypothesize that
      donepezil treatment may be beneficial for sleep apnea patients.

      Intervention: Patients will be administered donepezil or placebo. The study has a randomized,
      double-blind placebo-controlled design. Complete polysomnography will be performed at
      baseline, after 28 days of drug or placebo treatment, after 15 days drug or placebo washout
      and after 28 days of CPAP treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography parameters: respiratory parameters, sleep structure</measure>
    <time_frame>baseline, 28 days, 15 days, 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>baseline, 28 days, 15 days, 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil-treated sleep apnea patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-treated sleep apnea patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <description>donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days</description>
    <arm_group_label>Donepezil</arm_group_label>
    <other_name>Eranz, Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 1 p/day for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Non-active substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of obstructive sleep apnea according to American Academy of Sleep Medicine
             criteria

        Exclusion Criteria:

          -  body mass index &gt; 40

          -  use of psychoactive drugs

          -  presence of neurological, cardiological and pulmonary diseases
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Moraes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associacao Fundo de Incentivo a Psicofarmcologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucia Sukys-Claudino, MD</last_name>
    <role>Study Director</role>
    <affiliation>AFIP / UNIFESP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dalva Poyares, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AFIP/ UNIFESP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Tufik, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AFIP/ UNIFESP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucia Sukys Claudino, MD</last_name>
    <phone>(55-48)-9129-7576</phone>
    <email>lucia@neuromeddiagnosticos.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Walter Moraes, MD</last_name>
    <phone>(55-11)-5573-9238</phone>
    <email>walter.moraes@afip.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Sono / Associacao Fundo de Incentivo a Psicofarmacologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Sukys-Claudino, MD</last_name>
      <phone>(55-48)-9129-7576</phone>
      <email>lucia@neuromeddiagnosticos.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Walter Moraes, MD, PhD</last_name>
      <phone>(55-11)-5573-9238</phone>
      <email>walter.moraes@afip.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Sergio Tufik, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dalva Poyares, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Walter Andre dos Santos Moraes</name_title>
    <organization>AFIP</organization>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>donepezil</keyword>
  <keyword>pharmacological</keyword>
  <keyword>cholinergic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

